Lundbeck is hoping that additional cognitive claims for its blockbuster-in-the-making Brintellix can help set the drug apart from its antidepressant competition. The Danish drugmaker recently got a boost after an FDA committee backed the drug's ability to improve thinking, attention and decision-making in patients.
Whatever Takeda learned about Cambridge, MA-based Mersana Therapeutics over the course of its two-year collaboration, the experience left them eager for much, much more. The biotech announced today that the Japanese pharma company snagged ex-U.S. commercial rights to its lead preclinical antibody drug conjugate while expanding the realm of their partnership to include a range of new targets.
The patent office in India has slapped down an application from Tokyo-based Takeda Pharmaceutical for its single-dose Type 2 diabetes treatment dipeptidyl peptidase 4 (DPP-4) inhibitor.
Almost 7 years after licensing it from Novartis, Takeda picked up a regulatory green light from Japan's Ministry of Health, Labour and Welfare for its Haemophilus influenzae type B (Hib) vaccine. The vaccine, Vaxem Hib, is approved for use in children aged two months to under 5 years.
Takeda has enlisted Broad Institute Genomic Services to analyze samples taken from patients who participated in a Phase III trial of its recently approved multiple myeloma drug, Ninlaro.
Takeda has its eye on some serious growth--and to help it get there, it's bringing its U.K. sales force in-house. Beginning this June, 70 contract staffers--including those on teams for oncology and inflammatory bowel disease (IBD)--will become Takeda employees, a move that will nearly double Takeda's ranks in the U.K.
Takeda wants to get the ball rolling on some ambitious growth plans in 2016, and the company is bringing its U.K. sales force in-house to help it along the way.
Japanese pharma Takeda and Montreal's enGene have teamed up to develop gastrointestinal gene therapies using the latter company's Gene Pill delivery platform.
Top Japanese drugmakers are moving to sell off their noncore businesses and less profitable generic drugs to focus on new drugs that are protected by patents and that bring in millions more in revenue.
Osaka-based Takeda Pharmaceutical CEO Christophe Weber still needs to win over investors one year into running Japan's top and oldest drug company, Bloomberg reports, adding that the plan is to find new blockbusters in house and partnerships or acquisitions and bolster sales of generics.